Generic medication company Upsher-Smith Laboratories LLC reported on Tuesday the receipt of approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Bumetanide Tablets, USP in 0.5 mg, 1 mg and 2 mg for treating fluid retention in the body.
According to the company, Bumetanide Tablets are a generic version of the brand product, Bumex (bumetanide) Tablets.
The company will begin shipping Bumetanide Tablets to wholesalers in early February 2018.
Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dosage schedule have to be adjusted to the individual patient's needs, added the company.
For the 12 months ending November 2017, the bumetanide tablet market had US sales of approximately USD84.5m, according to IMS Health.
Fresenius Kabi Introduces Leucovorin Calcium Injection, USP
FDA Approves Dr. Reddy's Tosymra 10 mg, in the US Market
Dr. Reddy's Laboratories Announces the Launch of Propofol Injectable Emulsion, USP in the US Market
Amerigen awarded US FDA's approval for generic mixed amphetamine salts, extended-release capsules
Pharmaceutics International names new president and CEO
Amneal wins US FDA approval for Rivastigmine Transdermal System
Premier Expands Effort to Supply Shortage Generic Drugs
Ferring Pharmaceuticals Adds Two Products to its Reproductive Health Portfolio in the US
China's Bio-Thera Solutions Partners with Cipla to Market Key Cancer Biosimilar
EpicGenetics Moves into New Facility, Expanding Capacity by 4X
Amneal Pharmaceuticals appoints David A. Buchen as SVP, chief legal officer and corporate secretary
Ironwood Pharmaceuticals and Allergan reach agreement to resolve Mylan LINZESS patent litigation
Teva and Amgen Resolve Ongoing Dispute Over Teva's Generic Cinacalet HCl Product